CD19 and acute lymphoblastic leukemia: AUTO3, a bicistronic anti-CD19/CD22 CAR, was evaluated in the phase I AMELIA trial, inducing an 80% MRD-negativity in 15 pediatric and young adult patients with R/R B-ALL.